Clinical Trial Update: This is a 96-week, Multicenter Study in Patients With Neovascular AMD That Evaluates OCUL101 for Efficacy, Safety, Durability, and Pharmacokinetics, Comparing it With Another Treatment. The Study Will be Conducted in Two Parts, Part A and Part B. [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update describes a 96-week multicenter Phase 2/3 study of OCUL101 for neovascular age-related macular degeneration, with Part A and Part B, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• OCUL101

Snippet

Sponsor: Shenzhen Oculgen Biomedical Technology Co., Ltd. | Conditions: Adults With Neovascular Age-related Macular Degeneration | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING